Cargando…
The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial
Probiotics have been reported to ameliorate symptoms of type 2 diabetes mellitus (T2DM) in animal models and human studies. We previously demonstrated that oral administration of Lactobacillus reuteri ADR-3 reduced insulin resistance in high-fructose-fed (HFD) rats. In the present study, we first id...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235926/ https://www.ncbi.nlm.nih.gov/pubmed/30429496 http://dx.doi.org/10.1038/s41598-018-35014-1 |
_version_ | 1783370938038878208 |
---|---|
author | Hsieh, Ming-Chia Tsai, Wan-Hua Jheng, Yu-Pang Su, Shih-Li Wang, Shu-Yi Lin, Chi-Chen Chen, Yi-Hsing Chang, Wen-Wei |
author_facet | Hsieh, Ming-Chia Tsai, Wan-Hua Jheng, Yu-Pang Su, Shih-Li Wang, Shu-Yi Lin, Chi-Chen Chen, Yi-Hsing Chang, Wen-Wei |
author_sort | Hsieh, Ming-Chia |
collection | PubMed |
description | Probiotics have been reported to ameliorate symptoms of type 2 diabetes mellitus (T2DM) in animal models and human studies. We previously demonstrated that oral administration of Lactobacillus reuteri ADR-3 reduced insulin resistance in high-fructose-fed (HFD) rats. In the present study, we first identified another L. reuteri strain, ADR-1, which displayed anti-diabetes activity that reduced the levels of serum HbA1c and cholesterol and that increased antioxidant proteins in HFD rats. We further performed a randomized, double-blinded, placebo-controlled trial with a total of 68 T2DM patients to examine the beneficial effects of oral consumption of L. reuteri strains ADR-1 and ADR-3 and to investigate the associated changes in intestinal flora using a quantitative PCR method to analyze 16 S rRNA in fecal specimens. Significant reductions in HbA1c and serum cholesterol were observed in participants in the live ADR-1 consumption group (n = 22) after 3 months of intake when compared with those in the placebo group (n = 22). Although there was no significant difference in the HbA1c serum level among participants who consumed heat-killed ADR-3 (n = 24), the systolic blood pressure and mean blood pressure were significantly decreased after 6 months of intake. There was no obvious change in serum inflammatory cytokines or antioxidant proteins in participants after intaking ADR-1 or ADR-3, except for a reduction in IL-1β in the ADR-3 consumption group after 6 months of intake. With the analysis of fecal microflora, we found that L. reuteri or Bifidobacterium spp. were significantly increased in the ADR-1 and ADR-3 consumption groups, respectively, after 6 months of intake. Interestingly, a significant reduction in HbA1c was observed in the ADR-1 and ADR-3 consumption participants who displayed at least an 8-fold increase in fecal L. reuteri. We also observed that there was a significantly positive correlation between Bifidobacterium spp. and Lactobacillus spp. in participants with increased levels of fecal L. reuteri. In the ADR-1 intake group, the fecal Lactobacillus spp. level displayed a positive correlation with Bifidobacterium spp. but was negatively correlated with Bacteroidetes. The total level of fecal L. reuteri in participants in the ADR-3 consumption group was positively correlated with Firmicutes. In conclusion, L. reuteri strains ADR-1 and ADR-3 have beneficial effects on T2DM patients, and the consumption of different strains of L. reuteri may influence changes in intestinal flora, which may lead to different outcomes after probiotic intake. |
format | Online Article Text |
id | pubmed-6235926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62359262018-11-20 The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial Hsieh, Ming-Chia Tsai, Wan-Hua Jheng, Yu-Pang Su, Shih-Li Wang, Shu-Yi Lin, Chi-Chen Chen, Yi-Hsing Chang, Wen-Wei Sci Rep Article Probiotics have been reported to ameliorate symptoms of type 2 diabetes mellitus (T2DM) in animal models and human studies. We previously demonstrated that oral administration of Lactobacillus reuteri ADR-3 reduced insulin resistance in high-fructose-fed (HFD) rats. In the present study, we first identified another L. reuteri strain, ADR-1, which displayed anti-diabetes activity that reduced the levels of serum HbA1c and cholesterol and that increased antioxidant proteins in HFD rats. We further performed a randomized, double-blinded, placebo-controlled trial with a total of 68 T2DM patients to examine the beneficial effects of oral consumption of L. reuteri strains ADR-1 and ADR-3 and to investigate the associated changes in intestinal flora using a quantitative PCR method to analyze 16 S rRNA in fecal specimens. Significant reductions in HbA1c and serum cholesterol were observed in participants in the live ADR-1 consumption group (n = 22) after 3 months of intake when compared with those in the placebo group (n = 22). Although there was no significant difference in the HbA1c serum level among participants who consumed heat-killed ADR-3 (n = 24), the systolic blood pressure and mean blood pressure were significantly decreased after 6 months of intake. There was no obvious change in serum inflammatory cytokines or antioxidant proteins in participants after intaking ADR-1 or ADR-3, except for a reduction in IL-1β in the ADR-3 consumption group after 6 months of intake. With the analysis of fecal microflora, we found that L. reuteri or Bifidobacterium spp. were significantly increased in the ADR-1 and ADR-3 consumption groups, respectively, after 6 months of intake. Interestingly, a significant reduction in HbA1c was observed in the ADR-1 and ADR-3 consumption participants who displayed at least an 8-fold increase in fecal L. reuteri. We also observed that there was a significantly positive correlation between Bifidobacterium spp. and Lactobacillus spp. in participants with increased levels of fecal L. reuteri. In the ADR-1 intake group, the fecal Lactobacillus spp. level displayed a positive correlation with Bifidobacterium spp. but was negatively correlated with Bacteroidetes. The total level of fecal L. reuteri in participants in the ADR-3 consumption group was positively correlated with Firmicutes. In conclusion, L. reuteri strains ADR-1 and ADR-3 have beneficial effects on T2DM patients, and the consumption of different strains of L. reuteri may influence changes in intestinal flora, which may lead to different outcomes after probiotic intake. Nature Publishing Group UK 2018-11-14 /pmc/articles/PMC6235926/ /pubmed/30429496 http://dx.doi.org/10.1038/s41598-018-35014-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Hsieh, Ming-Chia Tsai, Wan-Hua Jheng, Yu-Pang Su, Shih-Li Wang, Shu-Yi Lin, Chi-Chen Chen, Yi-Hsing Chang, Wen-Wei The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
title | The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
title_full | The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
title_fullStr | The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
title_full_unstemmed | The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
title_short | The beneficial effects of Lactobacillus reuteri ADR-1 or ADR-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
title_sort | beneficial effects of lactobacillus reuteri adr-1 or adr-3 consumption on type 2 diabetes mellitus: a randomized, double-blinded, placebo-controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235926/ https://www.ncbi.nlm.nih.gov/pubmed/30429496 http://dx.doi.org/10.1038/s41598-018-35014-1 |
work_keys_str_mv | AT hsiehmingchia thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT tsaiwanhua thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT jhengyupang thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT sushihli thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT wangshuyi thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT linchichen thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT chenyihsing thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT changwenwei thebeneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT hsiehmingchia beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT tsaiwanhua beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT jhengyupang beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT sushihli beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT wangshuyi beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT linchichen beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT chenyihsing beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial AT changwenwei beneficialeffectsoflactobacillusreuteriadr1oradr3consumptionontype2diabetesmellitusarandomizeddoubleblindedplacebocontrolledtrial |